VEEV Stock Analysis: Veeva Systems | NYSE

Clinical Trials, Customer Management, Data Analytics, Regulatory Compliance

Total Rating 68

Safety 91

Buy Signal 2.00

Health Information Services
Industry Rotation: +12.9

Market Cap: 50.3B
Avg Turnover: 420M

Risk 3d forecast

Volatility36.2%

VaR 5^th Pctl5.43%

VaR vs Median-7.09%

Reward TTM

Sharpe Ratio0.36

Rel. Str. IBD96.8

Rel. Str. Peer Group96.2 pctl

Character TTM

Beta0.556

Beta Downside0.555

Hurst Exponent0.493

Choppyness6.68%

Drawdowns 3y

Max DD50.55%

CAGR/Max DD0.39

CAGR/Mean DD1.28

EPS (Earnings per Share)

EPS CAGR: 24.64%
EPS Trend: 97.3%

Last SUE: 1.17
Qual. Beats: 16

Revenue

Rev. CAGR: 15.95%
Rev. Trend: 100.0%

Last SUE: 3.23
Qual. Beats: 11

Warnings

No concerns identified

Tailwinds

Supp Ema8

Rs Leader

Idiosyncratic Leader

Confidence

Tailwind

Seasonality 11.7 years of data

Jan +0.2% 7

Feb -0.5% 8

Mar +1.6% 29

Apr -1.2% 13

May +8.8% 43

Jun +2.5% 22

Jul +3.7% 23

Aug +0.2% 7

Sep -6.0% 59

Oct -4.6% 27

Nov -1.4% 2

Dec -10.6% 72

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: VEEV Veeva Systems

Veeva Systems Inc. (NYSE: VEEV) is a US-based cloud software provider that operates exclusively within the life sciences industry, serving pharmaceutical, biotechnology, and consumer products companies across global markets including North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is classified within the GICS Health Care Technology sub-industry and is one of the largest pure-play vertical SaaS providers serving regulated industries.

The companys product portfolio is organized into three primary cloud platforms. Veeva Commercial Cloud includes the Vault CRM Suite, Veeva Medical, Veeva PromoMats, and Veeva Crossix analytics, supporting sales, marketing, and medical content management. Veeva Data Cloud delivers customer reference data (OpenData), deep data (Link), longitudinal patient data (Compass), and CRM engagement metrics (Pulse). Veeva Development Cloud supports clinical trials, data management, safety, and regulatory information management, complemented by the Veeva Quality Cloud and Business Consulting services.

In addition to software subscriptions, Veeva generates revenue from professional and support services such as implementation planning, systems integration, data migration, training, and managed services. This services component is typical of enterprise SaaS vendors serving regulated industries, where deployment complexity often requires extensive customer enablement.

The company was incorporated in 2007 in Pleasanton, California, originally as Verticals onDemand, Inc., before adopting its current name in April 2009. Veeva has been publicly traded since its October 2013 IPO and currently carries a large-cap market capitalization.

Headlines to Watch Out For

Vault subscription revenue growth drives operating margin expansion
Biotech funding pressure caps new customer subscription growth
Pharma regulatory compliance demand fuels RIM segment revenue

Piotroski VR-10 (Strict) 5.0

Net Income: 1.01b TTM > 0 and > 6% of Revenue
FCF/TA: 0.18 > 0.02 and ΔFCF/TA 1.53 > 1.0
NWC/Revenue: 187.7% < 20% (prev 193.4%; Δ -5.68% < -1%)
CFO/TA 0.18 > 3% & CFO 1.67b > Net Income 1.01b
Net Debt (-7.09b) to EBITDA (1.30b): -5.47 < 3
Current Ratio: 5.46 > 1.5 & < 3
Outstanding Shares: last quarter (165.1m) vs 12m ago -1.32% < -2%
Gross Margin: 74.96% > 18% (prev 75.59%; Δ -0.63% > 0.5%)
Asset Turnover: 40.54% > 50% (prev 37.11%; Δ 3.44% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)

Altman Z'' 10.00

A: 0.72 (Total Current Assets 7.95b - Total Current Liabilities 1.46b) / Total Assets 9.06b
B: 0.54 (Retained Earnings 4.90b / Total Assets 9.06b)
C: 0.15 (EBIT TTM 1.25b / Avg Total Assets 8.53b)
D: 4.56 (Book Value of Equity 7.43b / Total Liabilities 1.63b)
Altman-Z'' = 12.24 = AAA

Beneish M -2.93

DSRI: 1.03 (Receivables 565.6m/472.4m, Revenue 3.46b/2.97b)
GMI: 1.01 (GM 75.59% / 74.96%)
AQI: 0.92 (AQ_t 0.10 / AQ_t-1 0.11)
SGI: 1.17 (Revenue 3.46b / 2.97b)
TATA: -0.07 (NI 1.01b - CFO 1.67b) / TA 9.06b)
Beneish M = -2.93 (Cap -4..+1) = A

What is the price of VEEV shares?

As of October 25, 2026, the stock is trading at USD 323.04 with a total of 1,371,147 shares traded. Over the past week, the price has changed by +4.09%, over one month by +19.31%, over three months by +79.89% and over the past year by +10.82%.

Current recommended Stop Loss: 311.70 (which is 3.5% or 1.2 ATR below the current price).

Is VEEV a buy, sell or hold?

Veeva Systems has received a consensus analysts rating of 4.07. Therefore, it is recommended to buy VEEV.

StrongBuy: 13
Buy: 7
Hold: 8
Sell: 0
StrongSell: 1

What are the forecasts/targets for the VEEV price?

Analysts Target Price	297	-8%

Veeva Systems (VEEV) - Fundamental Data Overview as of 19 October 2026

Market Cap USD = 50.3b (50.3b USD * 1.0 USD.USD)
P/E Trailing = 50.8787
P/E Forward = 30.2115
P/S = 14.5311
P/B = 5.8988
P/EG = 1.2067
Revenue TTM = 3.46b USD
EBIT TTM = 1.25b USD
EBITDA TTM = 1.30b USD
Long Term Debt = 137.1m USD (estimated: total debt 151.7m - short term 14.6m)
Short Term Debt = 14.6m USD (from shortTermDebt, last quarter)
Debt = 151.7m USD (from shortLongTermDebtTotal, last quarter) (leases 151.7m already included)
Net Debt = -7.09b USD (calculated: Debt 151.7m - CCE 7.24b)
Enterprise Value = 43.2b USD (50.3b + Debt 151.7m - CCE 7.24b)
Interest Coverage Ratio = unknown (Ebit TTM 1.25b / Interest Expense TTM 0.0)
EV/FCF = 26.28x (Enterprise Value 43.2b / FCF TTM 1.64b)
FCF Yield = 3.81% (FCF TTM 1.64b / Enterprise Value 43.2b)
FCF Margin = 47.49% (FCF TTM 1.64b / Revenue TTM 3.46b)
Net Margin = 29.34% (Net Income TTM 1.01b / Revenue TTM 3.46b)
Gross Margin = 74.96% ((Revenue TTM 3.46b - Cost of Revenue TTM 865.9m) / Revenue TTM)
Gross Margin QoQ = 75.00% (prev 74.98%)
Tobins Q-Ratio = 4.76 (Enterprise Value 43.2b / Total Assets 9.06b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 151.7m)
Taxrate = 23.55% (312.6m / 1.33b)
NOPAT = 957.9m (EBIT 1.25b * (1 - 23.55%))
Current Ratio = 5.46 (Total Current Assets 7.95b / Total Current Liabilities 1.46b)
Debt / Equity = 0.02 (Debt 151.7m / totalStockholderEquity, last quarter 7.43b)
Debt / EBITDA = -5.47 (Net Debt -7.09b / EBITDA 1.30b)
Debt / FCF = -4.32 (Net Debt -7.09b / FCF TTM 1.64b)
Total Stockholder Equity = 7.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.90% (Net Income 1.01b / Total Assets 9.06b)
RoE = 14.00% (Net Income TTM 1.01b / Total Stockholder Equity 7.25b)
RoCE = 16.97% (EBIT 1.25b / Capital Employed (Equity 7.25b + L.T.Debt 137.1m))
RoIC = 12.86% (NOPAT 957.9m / Invested Capital 7.45b)
WACC = 7.49% (E(50.3b)/V(50.4b) * Re(7.51%) + D(151.7m)/V(50.4b) * Rd(0.0%) * (1-Tc(0.24)))
Discount Rate = 7.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.30 | Cagr: 0.18%
[DCF] Terminal Value 77.97% ; FCFF base≈1.52b ; Y1≈1.74b ; Y5≈2.56b
[DCF] Fair Price = 281.6 (EV 38.5b - Net Debt -7.09b = Equity 45.6b / Shares 161.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.31 | EPS CAGR: 24.64% | SUE: 1.17 | # QB: 16
Revenue Correlation: 99.96 | Revenue CAGR: 15.95% | SUE: 3.23 | # QB: 11
EPS current Quarter (2026-10-31): EPS=2.34 | Chg30d=+0.00% | Revisions=+89% | Analysts=26
EPS current Year (2027-01-31): EPS=9.24 | Chg30d=+0.00% | Revisions=+90% | GrowthEPS=+14.0% | GrowthRev=+15.5%
EPS next Year (2028-01-31): EPS=10.25 | Chg30d=+0.00% | Revisions=+89% | GrowthEPS=+11.0% | GrowthRev=+12.3%
[Analyst] Revisions Ratio: +96% (up=75, down=0)